CN112867730A - 用于治疗高胰岛素低血糖症的阿维西特 - Google Patents

用于治疗高胰岛素低血糖症的阿维西特 Download PDF

Info

Publication number
CN112867730A
CN112867730A CN201980068180.8A CN201980068180A CN112867730A CN 112867730 A CN112867730 A CN 112867730A CN 201980068180 A CN201980068180 A CN 201980068180A CN 112867730 A CN112867730 A CN 112867730A
Authority
CN
China
Prior art keywords
subject
acitretin
hypoglycemia
administered
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980068180.8A
Other languages
English (en)
Chinese (zh)
Inventor
科琳·M·克雷格
丽莎·波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylyx Pharmaceuticals Inc
Original Assignee
Eiger Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Biopharmaceuticals Inc filed Critical Eiger Biopharmaceuticals Inc
Publication of CN112867730A publication Critical patent/CN112867730A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980068180.8A 2018-10-15 2019-10-15 用于治疗高胰岛素低血糖症的阿维西特 Pending CN112867730A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862745915P 2018-10-15 2018-10-15
US62/745,915 2018-10-15
US201862746229P 2018-10-16 2018-10-16
US62/746,229 2018-10-16
US201962823493P 2019-03-25 2019-03-25
US62/823,493 2019-03-25
PCT/US2019/056278 WO2020081534A1 (en) 2018-10-15 2019-10-15 Avexitide for the treatment of hyperinsulinemic hypoglycemia

Publications (1)

Publication Number Publication Date
CN112867730A true CN112867730A (zh) 2021-05-28

Family

ID=70283142

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980068180.8A Pending CN112867730A (zh) 2018-10-15 2019-10-15 用于治疗高胰岛素低血糖症的阿维西特

Country Status (10)

Country Link
US (1) US20210338780A1 (https=)
EP (2) EP4233842A3 (https=)
JP (2) JP2022513351A (https=)
CN (1) CN112867730A (https=)
AU (2) AU2019359807B2 (https=)
BR (1) BR112021006968A2 (https=)
CA (1) CA3115527A1 (https=)
CL (1) CL2021000892A1 (https=)
IL (2) IL314504A (https=)
WO (1) WO2020081534A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022271753A1 (en) 2021-06-21 2022-12-29 Eiger Biopharmaceuticals, Inc. Treatment of congenital hyperinsulinism with avexitide
CN121219002A (zh) * 2023-04-21 2025-12-26 小利兰斯坦福大学董事会 Glp-1r拮抗作用改善胃肠外科手术后的营养

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191395A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
WO2018094404A1 (en) * 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8076288B2 (en) * 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
WO2013120022A2 (en) * 2012-02-08 2013-08-15 Seneb Biosciences, Inc. Treatment of hypoglycemia
US20160185837A1 (en) * 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
US10653753B2 (en) * 2016-03-04 2020-05-19 Eiger Biopharmaceuticals, Inc. Treatment of hyperinsulinemic hypoglycemia with exendin-4 derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016191395A1 (en) * 2015-05-22 2016-12-01 The Bot Of The Leland Stanford Junior University Treatment of post-bariatric hypoglycemia with exendin(9-39)
WO2018094404A1 (en) * 2016-11-21 2018-05-24 Eiger Biopharmaceuticals, Inc. Buffered formulations of exendin (9-39)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
COLLEEN M CRAIG等: "Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia", DIABETES OBES METAB., vol. 20, no. 2, pages 352 - 361, XP002806682, DOI: 10.1111/dom.13078 *

Also Published As

Publication number Publication date
WO2020081534A1 (en) 2020-04-23
BR112021006968A2 (pt) 2021-07-27
IL282059A (en) 2021-05-31
AU2019359807A1 (en) 2021-05-13
US20210338780A1 (en) 2021-11-04
EP3867266A1 (en) 2021-08-25
AU2025208421A1 (en) 2025-08-14
CL2021000892A1 (es) 2021-11-12
CA3115527A1 (en) 2020-04-23
JP2025000798A (ja) 2025-01-07
IL314504A (en) 2024-09-01
JP2022513351A (ja) 2022-02-07
EP3867266A4 (en) 2022-07-13
AU2019359807B2 (en) 2025-04-24
EP4233842A2 (en) 2023-08-30
EP4233842A3 (en) 2023-10-25

Similar Documents

Publication Publication Date Title
Thethi et al. Efficacy, safety and cardiovascular outcomes of once‐daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme
US11738086B2 (en) Methods of using buffered formulations of exendin (9-39)
US12220444B2 (en) Treatment of hyperinsulinemic hypoglycemia with GLP-1 antagonist exendin(9-39)
JP2019535734A5 (https=)
JP2025000798A (ja) 高インシュリン血症性低血糖症の治療のためのアベキシド
AU2021213064A1 (en) Therapeutic uses of tirzepatide
TW202417035A (zh) 提派肽(tirzepatide)組合物及用途
HK40014636A (en) Buffered formulations of exendin (9-39)
HK40014636B (en) Buffered formulations of exendin (9-39)
San Francisco Late-Breaking Abstracts

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20250313

Address after: Massachusetts, USA

Applicant after: Amylyx Pharmaceuticals Inc.

Country or region after: U.S.A.

Address before: California, USA

Applicant before: EIGER BIOPHARMACEUTICALS, Inc.

Country or region before: U.S.A.

TA01 Transfer of patent application right